Welcome - Register - Login - Help/FAQ - 0 items

Search
Enter keywords, a title or
a report id number below.

Advanced


	Select a currency for use throughout the site

Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure

Electronic

Live Chat Live Help Software for Website

Thought Leader Insight & Analysis Report - Inflammatory Bowel Disease Q2 2011

Medpredict, June 2011, Pages: 140


	Description



		Table of Contents


		Enquire before Buying


		Send to a Friend

Gastroenterology Thought Leader Panel #12 summarizes our discussions with six internationally recognized experts in the treatment of Crohn’s disease and ulcerative colitis. These took place following DDW, May 2011.

The Panel was most interested in opining on recent clinical data related to four groups of therapeutics: TNF, integrin/adhesion/MAdCAM, IL-23 and JAK. They predict the likelihood of approvals and use in the treatment of inflammatory bowel disease. Key mechanisms discussed in this report include TNF, integrin/MAdCAM, p40 (IL-23, IL-12, p19), IL-6 / JAK1 / JAK3, IL-17, CCR9 and stem cell transplant.

For enquiries please call us on:

+353-1-415-1241 (GMT Office Hours)

1-917-300-0470 (EST Office Hours)